Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs", being held later today, September 14, 2026

Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that Sarit Hashkes, President of its wholly owned subsidiary Filament Health Corp. ("Filament"), will deliver oral comments at the United States Food and Drug Administration ("FDA") public hearing on Considerations for Potential Future Therapeutic Use of Psychedelic Drugs, being held virtually and in person today, September 14, 2026.

The hearing has been convened by FDA's Center for Drug Evaluation and Research to gather input on the development, evaluation and potential future therapeutic use of psychedelic drugs. Filament is among the organizations providing oral remarks during the public comment period. The full hearing will be streamed live on the FDA's youtube channel. https://www.youtube.com/live/5Kg1gj3KbAI - again, Sarit will be speaking around 3:40pm ET. More info on the hearing's agenda: https://www.fda.gov/media/194795/download?attachment

PEX010 is Filament's patented, standardized, GMP manufactured botanical psilocybin drug candidate, produced using proprietary extraction, purification and stabilization methods that give investigators consistent composition across every dose, every study and every research site. On April 30, 2026, the Company completed its previously announced acquisition of Filament Health Corp., including its portfolio of 77 issued patents across 13 patent families and its lead drug candidate, PEX010. Filament supplies PEX010 as an investigational drug product. Participation in the FDA public hearing does not constitute an endorsement of the Company, of Filament or of PEX010 by FDA or by any other regulatory authority. PEX010 has not been approved by FDA or by any other regulatory authority for any indication.

About Rhelion Life Sciences: Rhelion Life Sciences is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world. For additional information: Todd Shapiro Chief Executive Officer & Director Tel: 647-204-7129 Email: [email protected] Website: www.Rhelion.com Cautionary Statement Regarding Forward-Looking Statements This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's...